株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

バキュロウイルスIAP 反復配列5:パイプライン製品の分析

Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 408080
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
バキュロウイルスIAP 反復配列5:パイプライン製品の分析 Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019
出版日: 2019年08月30日 ページ情報: 英文 88 Pages
概要

当レポートでは、バキュロウイルスIAP 反復配列5を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

バキュロウイルスIAP 反復配列5 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Biomics Biotechnologies Co., Ltd.
  • Bioneer Corporation
  • Boehringer Ingelheim GmbH
  • MimiVax, LLC
  • Optimum Therapeutics, LLC
  • Polyplus-Transfection SA

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Biomics Biotechnologies Co Ltd, H2 2019
  • Pipeline by Boehringer Ingelheim International GmbH, H2 2019
  • Pipeline by Canget BioTekpharma LLC, H2 2019
  • Pipeline by IMV Inc, H2 2019
  • Pipeline by MimiVax LLC, H2 2019
  • Pipeline by Optimum Therapeutics LLC, H2 2019
  • Pipeline by Oxford Vacmedix UK Ltd, H2 2019
  • Pipeline by Polyplus-Transfection SA, H2 2019
  • Pipeline by Stemline Therapeutics Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC1918TDB

Summary:

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 20 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia.

The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 8 and 2 respectively. Similarly, the universities portfolio in Phase II, Phase 0 and Preclinical stages comprises 1, 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Bladder Cancer, Melanoma, Prostate Cancer, Autoimmune Disorders, Bone Metastasis, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Colon Carcinoma, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Lymphoma, Malignant Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Relapsed Multiple Myeloma and Solid Tumor.

Furthermore, this report also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
  • The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development
    • Biomics Biotechnologies Co Ltd
    • Boehringer Ingelheim International GmbH
    • Canget BioTekpharma LLC
    • IMV Inc
    • MimiVax LLC
    • Optimum Therapeutics LLC
    • Oxford Vacmedix UK Ltd
    • Polyplus-Transfection SA
    • Stemline Therapeutics Inc
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles
    • Antibody to Target Survivin for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BGA-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-1361849 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BKM-1644 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BKM-1740 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DPX-Survivac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-118 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MV-2C2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MX-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OVM-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SL-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UC-112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Autoimmune Diseases and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Colon Carcinoma and Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Neuroblastoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target BIRC5 for Relapsed Multiple Myeloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products
  • Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 12, 2019: New Phase 2 clinical trial results continue to demonstrate potential clinical benefit of IMV's DPX-survivac in combination with Merck's Keytruda in patients with DLBCL
      • Jun 04, 2019: IMV to provide update on phase 2 clinical results with Merck Keytruda in DLBCL by means of conference Call and Webcast
      • Jun 01, 2019: Phase II trial shows favorable response for patients receiving combination therapy with SurVaxM
      • Jun 01, 2019: Imv presents new positive data from phase 2 monotherapy arm of its decide1 trial in advanced ovarian cancer and continued duration of clinical benefits to patients with progression free survival
      • May 16, 2019: IMV to present new data at 2019 ASCO annual meeting from its Phase 2 clinical trial evaluating DPX-Survivac in Ovarian Cancer
      • Apr 18, 2019: IMV to provide updated clinical data at 2019 ASCO annual meeting on lead candidate DPX-Survivac in Ovarian Cancer and other solid tumors
      • Mar 26, 2019: Initial phase 2 data from an IMV clinical study continues to demonstrate DPX-Survivac's prior trend as a potential monotherapy treatment for advanced ovarian cancer
      • Jan 29, 2019: IMV announces clinical update for DPX-Survivac program in ovarian cancer following positive feedback from U.S. FDA
      • Dec 13, 2018: IMV presents updated positive data from phase 1b/2 combination clinical trial in advanced ovarian cancer at 2018 ESMO Immuno-Oncology Congress
      • Dec 10, 2018: IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac's Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018
      • Nov 28, 2018: Brain Cancer Immunotherapy SurVaxM extends survival, even in hard-to-treat patients
      • Nov 22, 2018: IMV amends Phase Ib/II trial of recurrent ovarian cancer drug
      • Nov 16, 2018: Stemline Therapeutics announces oral presentation of SL-701 phase 2 data in second-line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)
      • Oct 16, 2018: Stemline Therapeutics announces SL-701 clinical data to be featured, including an Oral Presentation, at upcoming ESMO 2018 Congress
      • Sep 18, 2018: IMV announces early positive results from phase 2 clinical trial of lead candidate DPX-Survivac in combination with Merck's Keytruda in patients with DLBCL
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top